Hanrahan Jessie 4

4 · Solid Biosciences Inc. · Filed Feb 18, 2026

AI-generated summary of this filing

Updated Feb 19, 2026

Solid Biosciences (SLDB) Chief Regulatory Officer Jessie Hanrahan Sells Shares

What Happened

Jessie Hanrahan, Chief Regulatory Officer of Solid Biosciences (SLDB), had 8,125 restricted stock units (RSUs) convert into common shares on Feb 13, 2026 and then sold 4,134 of those shares in an open-market sell-to-cover transaction on Feb 18, 2026. The sale generated approximately $24,074 (weighted-average price $5.82). The RSU conversion shows $0 exercise price (no cash paid to receive the shares).
Net from these events Hanrahan retained 3,991 shares (8,125 converted minus 4,134 sold). The sale was an automated sell-to-cover to satisfy tax withholding, not a discretionary trade.

Key Details

Transaction dates: RSU conversion/exercise (reported as M) on 2026-02-13; open-market sale (S) on 2026-02-18.
Sale details: 4,134 shares sold for total proceeds reported as $24,074; weighted-average sale price $5.82; individual sale prices ranged $5.23–$6.14.
RSU/derivative details: 8,125 RSUs converted to common shares at $0.00 (no cash exercise price).
Shares after transactions: net increase of 3,991 shares to Hanrahan’s holdings from this vesting and sell-to-cover.
Footnotes of note:
- RSUs are contingent rights to one share each (F1).
- The Feb 18 sale was automatic to cover withholding taxes following RSU vesting (sell-to-cover instruction adopted Aug 16, 2024); not a discretionary sale (F2).
- The reported sale price is a weighted average; shares were sold at prices between $5.23 and $6.14 (F3).
- RSUs were originally granted Feb 13, 2024 and vest over four years with 25% vesting each anniversary (F4).
Filing timeliness: Form 4 was filed on Feb 18, 2026. The RSU conversion on Feb 13 appears to have been reported one business day late (due date would generally be within two business days; Feb 16 was a federal holiday), while the Feb 18 sale was reported same day.

Context

These transactions reflect RSU vesting and an automated sell-to-cover for taxes. Such sell-to-cover trades are routine and do not necessarily signal an insider’s view of the company’s prospects.
For derivative entries: the “M” code indicates conversion/exercise of a derivative (here, RSUs converting into common shares). The immediate or subsequent sale of some shares to cover taxes is common after vesting.

Form 4

Period: 2026-02-13

Chief Regulatory Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-13+8,125→ 78,452 total
Sale
Common Stock
[F2][F3]
2026-02-18$5.82/sh−4,134$24,074→ 74,318 total
Exercise/Conversion
Restricted Stock Units
[F1][F4]
2026-02-13−8,125→ 16,250 total
→ Common Stock (8,125 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
[F2]This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
[F4]The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Signature

/s/ Kimberly Cornwell as attorney-in-fact for Jessie Hanrahan|2026-02-18

1 file